Bausch Health Defeats Shareholder Suit Over Spinoff, Drug Patent

Bausch Health Cos. convinced a federal court to dismiss, for now, allegations that executives misled investors about the spin-off of Bausch + Lomb, and other corporate liabilities.

Most of the statements shareholders challenged were forward-looking expressions of belief that were inactionable, the US District Court for the District of New Jersey said Wednesday when it dismissed the proposed class suit without prejudice in an unpublished opinion.

Statements that implied Bausch had moved beyond “legacy legal issues” from when it went by Valeant Pharmaceuticals International Inc. may have been misleading, but the plaintiffs failed to allege executives spoke with ...